The master formulation record includes ingredients, equipment, and preparation instructions for compounded products.

Dose equals 400 mg/m2 times 1.5 m2 equals 600 mg of 5-FU needed for the IV bolus based on the patients BSA.

There are 29 days' supply of NPH U-100 insulin in a 10 mL vial when dispensed at 17 units b.i.d.

To determine the days' supply, we first calculate the total units in the vial and then divide by the daily usage. Since NPH U-100 insulin contains 100 units/mL, a 10 mL vial contains 1,000 units. The patient requires 34 units per day (17 units b.i.d.), leading to a total of 29 days' supply.

A) 6 This choice is incorrect because 6 days' supply would imply that only 204 units are used, which is significantly less than the total available units in the vial. At a dosage of 34 units per day, the vial would last much longer than just 6 days.

B) 15 Choosing 15 days' supply suggests a total consumption of 510 units. However, with a daily requirement of 34 units, the vial would last well beyond this estimate, as it contains 1,000 units. Therefore, 15 days does not represent a realistic calculation based on the prescribed dosage.

C) 29 This is the correct answer because it accurately reflects the total days' supply derived from the calculation. With 1,000 units available and a daily requirement of 34 units, the patient will have enough insulin for 29 days.

D) 59 This option is incorrect as it implies that the patient would use only 17 units per day, which is inconsistent with the provided b.i.d. dosage of 34 units daily. If the patient were to use insulin for 59 days at that rate, it would require 2,006 units, exceeding the amount available in the vial.

Conclusion Calculating the days' supply of medication is crucial for patient care and ensures that the patient has enough insulin while adhering to their prescribed dosage. In this scenario, with a total of 1,000 units available and a daily consumption of 34 units, the vial will last for 29 days, providing the necessary supply for the patient to manage their condition effectively.

Cyclosporine an immunosuppressant is commonly prescribed to prevent organ rejection after transplants like a kidney transplant by suppressing the immune response.

Reverse distributor is the company that takes back expired drugs.

Reverse distributors specialize in managing the return and disposal of expired or unused pharmaceuticals, ensuring compliance with regulations while allowing healthcare facilities to recover value from their inventories. These entities play a crucial role in the pharmaceutical supply chain by facilitating the safe and efficient return of drugs.

A) Secondary wholesaler Secondary wholesalers act as intermediaries in the distribution of pharmaceutical products, purchasing from manufacturers or primary wholesalers and reselling to pharmacies or healthcare providers. They do not focus on the return or disposal of expired drugs, making them unsuitable for this specific role in drug take-back programs.

B) Cancer drug repository Cancer drug repositories specifically handle the collection and redistribution of cancer medications that are unused and unexpired, aimed at helping patients in need. While they provide a valuable service, they do not typically manage expired drugs, which distinguishes them from reverse distributors focused on the broader scope of pharmaceutical returns.

C) Reverse distributor Reverse distributors are explicitly designed to handle the return, processing, and disposal of expired and unused medications. They ensure that drugs are returned to manufacturers or disposed of properly, adhering to regulatory standards, thus making them the correct choice for managing expired pharmaceuticals.

D) Prime vendor Prime vendors serve as the main suppliers for healthcare facilities, providing them with the medications they need. Although they may assist in managing pharmaceutical inventories, they do not specialize in the return of expired drugs, as their primary function is to supply and replenish stock rather than to take back expired items.

Conclusion The role of a reverse distributor is crucial in the pharmaceutical industry, particularly in managing expired drugs, which is vital for regulatory compliance and safety. While other choices relate to drug distribution and management, only reverse distributors focus specifically on the take-back of expired pharmaceuticals, ensuring proper handling and disposal. This specialization underscores their importance in the healthcare supply chain.

A Class I recall involves products with a high risk of causing serious health problems or death requiring immediate action to remove them from the market.

31-Jul-15

The pharmacy technician should place the manufacturer's expiration date of July 31, 2015, on the medication's prescription label. This date is critical as it indicates the last day the manufacturer guarantees the medication's safety and efficacy.

A) 30-May-15 This date is earlier than the manufacturer's expiration date and does not reflect the full shelf life of the medication. It would be inappropriate to use this date since it may lead to premature disposal of the medication before the manufacturer has deemed it ineffective.

B) 31-Jul-15 This is the correct choice. The expiration date provided by the manufacturer should be used on the prescription label, as it represents the date until which the medication is expected to remain effective and safe for use.

C) 30-Apr-16 This date extends beyond the manufacturer's expiration date and would not be correct to use. It implies that the medication is effective for an additional year, which is misleading and could compromise patient safety.

D) 31-Jul-16 Like option C, this date also exceeds the manufacturer's expiration date. Labeling the medication with this date would incorrectly suggest that it remains effective for an entire year past the established expiration, which can be dangerous and unethical.

Conclusion In pharmacy practice, it is crucial to adhere to the manufacturer's expiration dates to ensure patient safety and medication efficacy. The technician must use July 31, 2015, as the expiration date on the prescription label, as it is the only date supported by the manufacturer. Using any other date could mislead patients and potentially put their health at risk.

Prilosec is used to treat GERD.

Prilosec, containing omeprazole, is a proton pump inhibitor that reduces stomach acid production, effectively alleviating symptoms associated with gastroesophageal reflux disease (GERD). Its mechanism of action directly targets the underlying cause of GERD, making it a suitable treatment option.

A) Zyrtec Zyrtec is an antihistamine primarily used to relieve allergy symptoms such as sneezing, runny nose, and itchy eyes. It does not address the acid-related conditions of the gastrointestinal tract, nor is it indicated for treating GERD or any similar reflux conditions.

B) Prilosec Prilosec is a proton pump inhibitor that specifically targets and reduces gastric acid production, making it effective for the treatment of GERD. By decreasing acid secretion, it helps heal the esophagus and relieve symptoms such as heartburn and acid regurgitation.

C) Zicam Zicam is an over-the-counter homeopathic remedy often marketed for alleviating cold symptoms. It has no impact on stomach acid levels or GERD, as its formulation is not designed to treat gastrointestinal issues, but rather respiratory ailments.

D) Mucinex Mucinex, containing guaifenesin, is an expectorant that helps loosen mucus in the airways, making it easier to cough out. While beneficial for respiratory conditions, it does not treat GERD, as it does not influence stomach acid production or esophageal reflux.

Conclusion Prilosec stands out as the appropriate medication for treating GERD due to its ability to inhibit stomach acid production. In contrast, the other options—Zyrtec, Zicam, and Mucinex—are designed for unrelated health issues, such as allergies and respiratory conditions, and thus lack efficacy in treating GERD. Understanding these distinctions is crucial for effective management of gastrointestinal disorders.

Take two tablets by mouth four times a day for diabetes mellitus.

The prescription indicates a dosage of "ii tabs po qid," which translates to taking two tablets by mouth four times daily, specifically for the condition of diabetes mellitus (dm). This instruction is essential for managing blood sugar levels effectively.

A) Take two tablets by mouth four times a day for dietary management. While the dosage frequency is correct, the condition specified is inaccurate. The abbreviation "dm" distinctly refers to diabetes mellitus, not dietary management. Therefore, this choice misrepresents the purpose of the medication.

B) Take two tablets by mouth four times a day for diabetes mellitus. This option accurately reflects both the prescribed dosage and the medical condition indicated by the prescription. The instruction effectively conveys the correct usage and frequency for managing diabetes mellitus.

C) Take two tablets by mouth daily for dietary management. This choice incorrectly states the frequency as "daily" instead of "four times a day," and it also misidentifies the condition as dietary management. Both aspects are critical errors in interpreting the prescription.

D) Take two tablets by mouth daily for diabetes mellitus. Although this option mentions diabetes mellitus, it incorrectly states the dosage frequency as "daily" rather than the prescribed "four times a day." Accurate dosing frequency is crucial for effective medication management.

Conclusion Understanding prescription instructions is vital for ensuring proper medication use. In this case, the correct interpretation is to take two tablets by mouth four times a day specifically for diabetes mellitus, as indicated by the prescription. Misunderstandings regarding frequency or purpose can lead to ineffective treatment and potential health risks.

ISMP warns that MS or MSO4 for morphine can be mistaken for magnesium sulfate a different drug with serious consequences if confused.

Aricept is indicated to treat mild, moderate, or severe dementia of the Alzheimer type.

Aricept, also known as donepezil, is a cholinesterase inhibitor that is specifically approved for the treatment of Alzheimer's disease, helping to improve cognitive function and slow the progression of symptoms in patients with this type of dementia.

A) Aricept As a cholinesterase inhibitor, Aricept works by increasing the levels of acetylcholine in the brain, which is often deficient in patients with Alzheimer's disease. This mechanism assists in improving memory, cognition, and overall functioning in individuals suffering from various stages of this condition.

B) Azilect Azilect, or rasagiline, is primarily used to treat symptoms of Parkinson's disease and is not indicated for the treatment of Alzheimer's disease. While it helps with motor symptoms in Parkinson's, it does not target the cognitive decline associated with dementia of the Alzheimer type.

C) Ambien Ambien, or zolpidem, is a sedative primarily prescribed for short-term treatment of insomnia. It is not indicated for Alzheimer's disease or any form of dementia, as its purpose is to induce sleep rather than address cognitive impairment or memory loss.

D) Atacand Atacand, or candesartan, is an antihypertensive medication used to treat high blood pressure and heart failure. It does not have indications for Alzheimer's disease and does not provide any therapeutic benefit for dementia-related cognitive decline.

Conclusion In summary, Aricept is the only medication listed that is specifically approved for the treatment of mild, moderate, or severe dementia of the Alzheimer type. Other options like Azilect, Ambien, and Atacand serve entirely different purposes and are not effective in managing Alzheimer's disease symptoms. Understanding the appropriate use of these medications is crucial for effective patient care in neurodegenerative conditions.

Class I recall is the best fit for this situation.

A Class I recall is issued when there is a reasonable probability that the use of, or exposure to, a product will cause serious adverse health consequences or death. In this case, the error of dispensing penicillin instead of acetaminophen could lead to severe allergic reactions in patients sensitive to penicillin, thus necessitating a Class I recall.

A) Class I This category is appropriate as it pertains to products that could cause serious health risks or death. Since the incorrect medication (penicillin) can lead to life-threatening allergic reactions in individuals who are allergic, the urgency and severity of the potential consequences justify this classification.

B) Class II Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, but the probability of serious harm is remote. In this scenario, the risk of a severe allergic reaction makes this classification unsuitable, as the situation poses a more serious risk than a temporary issue.

C) Class III A Class III recall applies to products that are not likely to cause adverse health consequences but violate labeling or manufacturing regulations. Given that the error here involves a potentially dangerous medication being dispensed, this classification fails to address the significant health risks involved.

D) Class IV There is no Class IV recall recognized by the FDA. The classification system includes only three classes, making this choice invalid. Thus, this option does not pertain to any legitimate recall scenario.

Conclusion In summary, the misdispensing of penicillin instead of acetaminophen 325 mg necessitates a Class I recall due to the serious health risks posed to patients, particularly those with penicillin allergies. The other categories do not adequately capture the severity of the situation, reaffirming the critical nature of responding to medication errors with appropriate recall classifications.

Developing an action plan and measures is the final step of successful RCA.

In a successful Root Cause Analysis (RCA), the conclusion involves formulating a comprehensive action plan to address the identified root causes and implement measures to prevent future occurrences. This step ensures that effective solutions are not only proposed but also actionable and measurable for monitoring progress.

A) Approve plan Approving a plan is a critical step in the implementation process; however, it is not the final step of RCA. This action typically occurs after the action plan has been developed, meaning that simply approving a plan does not encompass the full scope of addressing the root causes identified during RCA.

B) Assign blame Assigning blame contradicts the fundamental purpose of RCA, which aims to identify root causes without placing responsibility on individuals. This approach is counterproductive and can lead to a toxic culture that inhibits open discussion and collective problem-solving. RCA focuses on systemic issues rather than personal accountability.

C) Send diagram Sending a diagram may be part of the documentation process during RCA, particularly for visualizing the analysis and findings. However, it does not represent the final step in effectively addressing the identified issues. Diagrams serve as tools for communication rather than the actionable steps needed to resolve the root causes.

D) Develop action plan and measures This choice encapsulates the essence of RCA's final stage, where specific strategies and metrics are created to tackle the identified root causes. This step is crucial for ensuring that the analysis translates into practical solutions that can be implemented and monitored for effectiveness.

Conclusion The final step of a successful Root Cause Analysis is to develop an action plan and measures that address the root causes identified in the process. This ensures that the organization can effectively implement solutions, preventing recurrence of the issues. Other options, such as approving plans or assigning blame, do not fulfill the comprehensive requirements necessary to conclude RCA effectively.

Toprol XL 50 mg substituted with metoprolol tartrate 50 mg is a wrong drug error.

Substituting Toprol XL, an extended-release formulation, with metoprolol tartrate, an immediate-release formulation, constitutes a wrong drug error due to the differences in their pharmacokinetics and therapeutic effects. Such a substitution can lead to inadequate blood pressure control or adverse effects, emphasizing the importance of using the correct formulation.

A) wrong drug error This choice accurately identifies the nature of the error, as the substitution of Toprol XL with metoprolol tartrate involves replacing one drug formulation with another that is not therapeutically equivalent. The differing release mechanisms can significantly affect patient outcomes, making this a clear case of a wrong drug error.

B) administration error While administration errors involve mistakes in giving the correct drug, in this instance, the fundamental issue arises from substituting one drug for another entirely different formulation. The administration was technically correct regarding dosage, but the error lies in the choice of drug, thus this option does not capture the essence of the problem.

C) incorrect time error An incorrect time error refers to administering a medication at the wrong scheduled time. In this case, the primary issue is the substitution of one drug for another rather than timing discrepancies. Therefore, this choice does not pertain to the situation at hand.

D) not an error This option suggests that the substitution is acceptable, which is false. The significant differences between Toprol XL and metoprolol tartrate in terms of formulation and therapeutic use clearly indicate that this substitution is indeed a medication error.

Conclusion The substitution of Toprol XL 50 mg with metoprolol tartrate 50 mg represents a wrong drug error due to the critical differences in their release characteristics and pharmacological effects. Recognizing this type of error is essential in ensuring patient safety and effective treatment outcomes. Other choices do not accurately reflect the nature of the substitution error, underlining the importance of precise medication management in clinical practice.

Gowns worn during the preparation of hazardous nonsterile compounds must be selected based on the specific hazardous drugs being handled.

Selecting gowns based on the specific hazardous drugs ensures that the protective equipment is suitable for the type of exposure anticipated, enhancing safety for personnel. This aligns with USP Chapter 800 guidelines that emphasize the importance of appropriate PPE based on the nature of the substances being handled.

A) have seams or closures that could allow hazardous drugs to reach the skin This option is incorrect as gowns should not have seams or closures that compromise their protective barrier. The purpose of gowns is to prevent any hazardous drugs from contacting the skin, thus they must be designed to minimize any potential exposure.

C) be made of reusable material to absorb hazardous drug residue While reusable materials can be beneficial for some protective gear, gowns used for handling hazardous drugs should ideally be disposable or made of materials that do not absorb contaminants. This prevents the risk of residual contamination that can occur with reusable fabrics, which could lead to exposure.

D) have short sleeves and open cuffs to minimize hazardous drug exposure This choice is incorrect because short sleeves and open cuffs do not provide adequate protection against hazardous drugs. Gowns should have long sleeves and closed cuffs to ensure that there are no openings through which hazardous substances can escape and reach the skin.

Conclusion According to USP Chapter 800, the selection of gowns should be tailored to the specific hazardous drugs being handled to ensure maximum protection for personnel. Incorrect options either compromise safety or do not meet the necessary standards for handling hazardous materials. Proper gown selection is critical in maintaining a safe environment during the preparation of hazardous nonsterile compounds.